Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Glutamate imaging (GluCEST) reveals lower brain GluCEST contrast in patients on the psychosis spectrum.

Roalf DR, Nanga RPR, Rupert PE, Hariharan H, Quarmley M, Calkins ME, Dress E, Prabhakaran K, Elliott MA, Moberg PJ, Gur RC, Gur RE, Reddy R, Turetsky BI.

Mol Psychiatry. 2017 Sep;22(9):1298-1305. doi: 10.1038/mp.2016.258. Epub 2017 Jan 24.

2.

Identifying functional network changing patterns in individuals at clinical high-risk for psychosis and patients with early illness schizophrenia: A group ICA study.

Du Y, Fryer SL, Lin D, Sui J, Yu Q, Chen J, Stuart B, Loewy RL, Calhoun VD, Mathalon DH.

Neuroimage Clin. 2017 Oct 19;17:335-346. doi: 10.1016/j.nicl.2017.10.018. eCollection 2018.

3.

Mapping glutamate in subcortical brain structures using high-resolution GluCEST MRI.

Cai K, Singh A, Roalf DR, Nanga RP, Haris M, Hariharan H, Gur R, Reddy R.

NMR Biomed. 2013 Oct;26(10):1278-84. doi: 10.1002/nbm.2949. Epub 2013 Apr 3.

4.

Brain network characteristics separating individuals at clinical high risk for psychosis into normality or psychosis.

Choi SH, Kyeong S, Cho KIK, Yun JY, Lee TY, Park HY, Kim SN, Kwon JS.

Schizophr Res. 2017 Dec;190:107-114. doi: 10.1016/j.schres.2017.03.028. Epub 2017 Mar 18.

PMID:
28325573
5.

Increased Striatal and Reduced Prefrontal Cerebral Blood Flow in Clinical High Risk for Psychosis.

Kindler J, Schultze-Lutter F, Hauf M, Dierks T, Federspiel A, Walther S, Schimmelmann BG, Hubl D.

Schizophr Bull. 2018 Jan 13;44(1):182-192. doi: 10.1093/schbul/sbx070.

6.

Dynamic functional connectivity impairments in early schizophrenia and clinical high-risk for psychosis.

Du Y, Fryer SL, Fu Z, Lin D, Sui J, Chen J, Damaraju E, Mennigen E, Stuart B, Loewy RL, Mathalon DH, Calhoun VD.

Neuroimage. 2018 Oct 15;180(Pt B):632-645. doi: 10.1016/j.neuroimage.2017.10.022. Epub 2017 Oct 14.

PMID:
29038030
7.

Mapping the alterations in glutamate with GluCEST MRI in a mouse model of dopamine deficiency.

Bagga P, Crescenzi R, Krishnamoorthy G, Verma G, Nanga RP, Reddy D, Greenberg J, Detre JA, Hariharan H, Reddy R.

J Neurochem. 2016 Nov;139(3):432-439. doi: 10.1111/jnc.13771. Epub 2016 Oct 16.

8.

Magnetic resonance imaging of glutamate.

Cai K, Haris M, Singh A, Kogan F, Greenberg JH, Hariharan H, Detre JA, Reddy R.

Nat Med. 2012 Jan 22;18(2):302-6. doi: 10.1038/nm.2615.

9.

Longitudinal imaging reveals subhippocampal dynamics in glutamate levels associated with histopathologic events in a mouse model of tauopathy and healthy mice.

Crescenzi R, DeBrosse C, Nanga RP, Byrne MD, Krishnamoorthy G, D'Aquilla K, Nath H, Morales KH, Iba M, Hariharan H, Lee VM, Detre JA, Reddy R.

Hippocampus. 2017 Mar;27(3):285-302. doi: 10.1002/hipo.22693. Epub 2017 Feb 3.

10.

The Youth Mental Health Risk and Resilience Study (YouR-Study).

Uhlhaas PJ, Gajwani R, Gross J, Gumley AI, Lawrie SM, Schwannauer M.

BMC Psychiatry. 2017 Jan 26;17(1):43. doi: 10.1186/s12888-017-1206-5.

11.

Structural Brain Abnormalities in Youth With Psychosis Spectrum Symptoms.

Satterthwaite TD, Wolf DH, Calkins ME, Vandekar SN, Erus G, Ruparel K, Roalf DR, Linn KA, Elliott MA, Moore TM, Hakonarson H, Shinohara RT, Davatzikos C, Gur RC, Gur RE.

JAMA Psychiatry. 2016 May 1;73(5):515-24. doi: 10.1001/jamapsychiatry.2015.3463. Erratum in: JAMA Psychiatry. 2017 May 1;74(5):542. Erratum in: JAMA Psychiatry. 2017 May 1;74(5):541-542.

12.

Cortico-Striatal GABAergic and Glutamatergic Dysregulations in Subjects at Ultra-High Risk for Psychosis Investigated with Proton Magnetic Resonance Spectroscopy.

de la Fuente-Sandoval C, Reyes-Madrigal F, Mao X, León-Ortiz P, Rodríguez-Mayoral O, Solís-Vivanco R, Favila R, Graff-Guerrero A, Shungu DC.

Int J Neuropsychopharmacol. 2015 Sep 12;19(3):pyv105. doi: 10.1093/ijnp/pyv105.

13.

Hyperactivity of caudate, parahippocampal, and prefrontal regions during working memory in never-medicated persons at clinical high-risk for psychosis.

Thermenos HW, Juelich RJ, DiChiara SR, Mesholam-Gately RI, Woodberry KA, Wojcik J, Makris N, Keshavan MS, Whitfield-Gabrieli S, Woo TU, Petryshen TL, Goldstein JM, Shenton ME, McCarley RW, Seidman LJ.

Schizophr Res. 2016 May;173(1-2):1-12. doi: 10.1016/j.schres.2016.02.023. Epub 2016 Mar 7.

14.

Voxel-Based Morphometry in Individuals at Genetic High Risk for Schizophrenia and Patients with Schizophrenia during Their First Episode of Psychosis.

Chang M, Womer FY, Bai C, Zhou Q, Wei S, Jiang X, Geng H, Zhou Y, Tang Y, Wang F.

PLoS One. 2016 Oct 10;11(10):e0163749. doi: 10.1371/journal.pone.0163749. eCollection 2016. Erratum in: PLoS One. 2017 Jan 9;12 (1):e0170146.

15.

Corticolimbic hyper-response to emotion and glutamatergic function in people with high schizotypy: a multimodal fMRI-MRS study.

Modinos G, McLaughlin A, Egerton A, McMullen K, Kumari V, Barker GJ, Keysers C, Williams SC.

Transl Psychiatry. 2017 Apr 4;7(4):e1083. doi: 10.1038/tp.2017.53.

16.

Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk.

Cannon TD, Chung Y, He G, Sun D, Jacobson A, van Erp TG, McEwen S, Addington J, Bearden CE, Cadenhead K, Cornblatt B, Mathalon DH, McGlashan T, Perkins D, Jeffries C, Seidman LJ, Tsuang M, Walker E, Woods SW, Heinssen R; North American Prodrome Longitudinal Study Consortium.

Biol Psychiatry. 2015 Jan 15;77(2):147-57. doi: 10.1016/j.biopsych.2014.05.023. Epub 2014 Jun 12.

17.

Using molecular imaging to understand early schizophrenia-related psychosis neurochemistry: a review of human studies.

Schifani C, Hafizi S, Da Silva T, Watts JJ, Khan MS, Mizrahi R.

Int Rev Psychiatry. 2017 Dec;29(6):555-566. doi: 10.1080/09540261.2017.1396205. Epub 2017 Dec 8. Review.

PMID:
29219634
18.

Imaging of glutamate in the spinal cord using GluCEST.

Kogan F, Singh A, Debrosse C, Haris M, Cai K, Nanga RP, Elliott M, Hariharan H, Reddy R.

Neuroimage. 2013 Aug 15;77:262-7. doi: 10.1016/j.neuroimage.2013.03.072. Epub 2013 Apr 9.

19.

Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis.

Shakory S, Watts JJ, Hafizi S, Da Silva T, Khan S, Kiang M, Bagby RM, Chavez S, Mizrahi R.

Neuropsychopharmacology. 2018 Oct;43(11):2249-2255. doi: 10.1038/s41386-018-0163-0. Epub 2018 Jul 28.

PMID:
30087434
20.

Glutamate weighted imaging contrast in gliomas with 7 Tesla magnetic resonance imaging.

Neal A, Moffat BA, Stein JM, Nanga RPR, Desmond P, Shinohara RT, Hariharan H, Glarin R, Drummond K, Morokoff A, Kwan P, Reddy R, O'Brien TJ, Davis KA.

Neuroimage Clin. 2019;22:101694. doi: 10.1016/j.nicl.2019.101694. Epub 2019 Jan 29.

Supplemental Content

Support Center